
Dohmen Company expands into medical-device arena
Latest acquisition is Reglera, leading consulting firm for med devices and human tissue products
Cynthia LaConte, the acquisitive CEO of
For its part, Reglera provides a range of outsourced services, including quality control and document management (both for regulatory submissions and commercial operations), product development consulting, adverse event reporting, contract manufacturing and fulfillment, among others. “With over 500 clients we’ve worked with, we’ve seen it all, from the physician-entrepreneur to the largest med-device manufacturers around,” says CEO Clay Anselmo.
“As personalized medicine becomes an increasingly viable healthcare model, traditional lines between pharma, bio, tissue and devices begin to blur. Expanding our medical device capability became the next logical step in our strategic plan to provide a holistic suite of support services to Life Science companies that are making the transition to therapeutic care companies,” said LaConte.
Like its new parent, Reglera shares a “conflict free” business philosophy, according to Anselmo: The company delivers its work on a fee-for-service basis, not taking ownership of the products and staying apart from financial incentives from buyers. Potential synergies with the rest of the Dohmen organization—such as handling product distribution through Dohmen’s DDN Pharmaceutical Logistics unit—remain to be worked out.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.